Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology

OncoTargets and Therapy

Volumn 5, Issue , 2012, Pages 287-296

  Sherrill, Beth ^a   Kaye, James A ^a   Sandin, Rickard ^b   Cappelleri, Joseph C ^c   Chen, Connie ^d  

^a RTI HEALTH SOLUTIONS   (United States)

^b Global Outcomes Research Sollentuna   (Sweden)

^c Biostatistics   (United States)

^d Analytica International   (United States)

Author keywords

Cancer; Correlation; Progression endpoints

Indexed keywords

ADVANCED CANCER; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CANCER; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; DRUG RESPONSE; EVENT FREE SURVIVAL; EVIDENCE BASED MEDICINE; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; META ANALYSIS; METASTATIC MELANOMA; MULTIPLE CANCER; NONHODGKIN LYMPHOMA; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SOLID TUMOR; STOMACH CANCER;

EID: 84873931584     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S36683     Document Type: Review

References (65)

1. Broglio KR, Berry DA. Detecting an overall survival beneft that is derived from progression-free survival. J Natl Cancer Inst. 2009;101: 1642-1649.
2. Temple RJ. A regulatory authority's opinion about surrogate endpoints. In: Nimmo WS, Tucker GT, editors. Clinical Measurement in Drug Evaluation. New York: J Wiley; 1995.
3. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605-613.
4. Sargent D. General and statistical hierarchy of appropriate biologic endpoints. Oncology (Williston Park). 2006;20:5-9.
5. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol. 2003;21:1404-1411.
6. Sridhara R, Johnson JR, Justice R, Keegan P, Chakravarty A, Pazdur R. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. J Natl Cancer Inst. 2010;102:230-243.
7. Weir CJ, Walley RJ. Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Stat Med. 2006;25:183-203.
8. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8(4):431-440.
9. Lassere MN. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarkersurrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res. 2008;17(3):303-340.
10. Buyse M. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials. Cancer J. 2009;15:421-425.
11. Buyse M. Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer. Int J Clin Oncol. 2009; 14:95-101.
12. Hughes MD. Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer. Stat Methods Med Res. 2008;17:487-495.
13. Burzykowski T, Buyse M. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. Pharm Stat. 2006;5:173-186.
14. Sargent DJ, Hayes DF. Assessing the measure of a new drug: is survival the only thing that matters? J Clin Oncol. 2008;26:1922-1923.
15. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23:8664-8670.
16. Burzykowski T, Buyse M, Yothers G, Sakamoto J, Sargent D. Exploring and validating surrogate endpoints in colorectal cancer. Lifetime Data Anal. 2008;14:54-64.
17. Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol. 2007;25:4562-4568.
18. Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007;25:5218-5224.
19. Louvet C, de Gramont A, Tournigand C, Artru P, Maindrault-Goebel F, Krulik M. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer. 2001;91:2033-2038.
20. Torri V, Simon R, Russek-Cohen E, Midthune D, Friedman M. Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy. J Natl Cancer Inst. 1992;84:407-414.
21. Bast RC, Thigpen JT, Arbuck SG, et al. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol. 2007;107:173-176.
22. Vermorken JB, Parmar MK, Brady MF, et al. Clinical trials in ovarian carcinoma: study methodology. Ann Oncol. 2005;16 Suppl 8: viii20-viii29.
23. Molenberghs G, Buyse M, Geys H, Renard D, Burzykowski T, Alonso A. Statistical challenges in the evaluation of surrogate endpoints in randomized trials. Control Clin Trials. 2002;23:607-625.
24. Ng R, Pond GR, Tang PA, MacIntosh PW, Siu LL, Chen EX. Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006. Ann Oncol. 2008;19:481-486.
25. Sherrill B, Amonkar M, Wu Y, et al. Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. Br J Cancer. 2008;99:1572-1578.
26. Miksad RA, Zietemann V, Gothe R, et al. Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care. 2008;24:371-383.
27. Hackshaw A, Knight A, Barrett-Lee P, Leonard R. Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. Br J Cancer. 2005;93: 1215-1221.
28. Shi Q, Sargent DJ. Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. Int J Clin Oncol. 2009;14:102-111.
29. Fleming TR. Objective response rate as a surrogate end point: a commentary. J Clin Oncol. 2005;23:4845-4846.
30. Foster NR, Qi Y, Shi Q, et al. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer. 2011;117:1262-1271.
31. Johnson KR, Ringland C, Stokes BJ, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol. 2006;7:741-746.
32. National Cancer Institute. Small cell lung cancer treatment (PDQ®). 2011. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/smallcell-lung/healthprofessional/page4. Accessed November 14, 2011.
33. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26:4617-4625.
34. Knox JJ. Progression-free survival as endpoint in metastatic RCC? Lancet. 2008;372:427-429.
35. Kane RC, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006;12: 7271-7278.
36. Delea TE, Khuu A, Kay A, Zheng J, Baladi J F. Association between treatment effects on disease progression (DP) endpoints and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 27:15s, 2009 (suppl; abstr 5105).
37. Pharmaceutical Benefts Advisory Committee (PBAC). Public summary document for everolimus, tablets, 5 mg and 10 mg, Afnitor®. Australian Government, Department of Health and Ageing; 2010. Available from: http://www.commcarelink.health.gov.au/internet/main/publishing.nsf/ Content/pbac-psd-Everolimus-july10. Accessed January 25, 2011.
38. Heng DY, Xie W, Bjarnason GA, et al. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer. 2011;117:2637-2642.
39. Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol. 2009;27:2766-2771.
40. Michiels S, Le Maître A, Buyse M, et al. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol. 2009;10:341-350.
41. Ballman KV, Buckner JC, Brown PD, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 2007;9:29-38.
42. Shitara K, Ikeda J, Yokota T, et al. Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials. Invest New Drugs. 2011;4. Abstract.
43. Lee L, Wang L, Crump M. Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent nonHodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points. Ann Oncol. 2011;22:1392-1403.
44. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progressionfree and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26:527-534.
45. Beckman M. More clinical cancer treatments judged by progressionfree rather than overall survival. J Natl Cancer Inst. 2007;99: 1068-1069.
46. van Tilborg AA, de Vries A, de Bont M, Groenfeld LE, van der Kwast TH, Zwarthoff EC. Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet. 2000;9:2973-2980.
47. Mora J, Cheung NK, Gerald WL. Genetic heterogeneity and clonal evolution in neuroblastoma. Br J Cancer. 2001;85:182-189.
48. Marktel S, Marin D, Foot N, et al. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica. 2003;88:260-267.
49. d'Amore F, Chan E, Iqbal J, et al. Clonal evolution in t(14;18)positive follicular lymphoma, evidence for multiple common pathways, and frequent parallel clonal evolution. Clin Cancer Res. 2008;14: 7180-7187.
50. Fleischer F, Gaschler-Markefski B, Bluhmki E. A statistical model for the dependence between progression-free survival and overall survival. Stat Med. 2009;28:2669-2686.
51. Négrier S, Bushmakin AG, Cappelleri JC, et al. Using a Weibull parametric model for failure-time data to assess progression-free survival as a surrogate endpoint for overall survival in a trial of patients with metastatic renal cell carcinoma. Presented at the European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 23-27, 2011.
52. de Gramont A, Hubbard J, Shi Q, et al. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol. 2010;28:460-465.
53. Dejardin D, Lesaffre E, Verbeke G. Joint modeling of progressionfree survival and death in advanced cancer clinical trials. Stat Med. 2010;29:1724-1734.
54. Rondeau V, Pignon J P, Michiels S. A joint model for the dependence between clustered times to tumour progression and deaths: a metaanalysis of chemotherapy in head and neck cancer. Stat Methods Med Res. 2011 Oct 23. [Epub ahead of print].
55. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of anticancer medicinal products in man. 2005. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientifc_guideline/2009/12/ WC500017748.pdf. Accessed January 13, 2011.
56. Food and Drug Administration. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. Rockville, MD: US Department of Health and Human Services; 2007. Available from: http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/ GuidanceDocuments/default.htm. Accessed October 11, 2010.
57. Food and Drug Administration. Guidance for industry [draft]: clinical trial endpoints for the approval of non-small cell lung cancer drugs and biologics. Rockville, MD: US Department of Health and Human Services; 2011. Available from: http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/ default.htm. Accessed November 14, 2011.
58. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet. 2000;356:373-378.
59. Wilkerson J, Fojo T. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival. Cancer J. 2009;15:379-385.
60. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics. 2000;1:49-67.
61. Rose PG, Tian C, Bookman MA. Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;117:324-329.
62. Burzykowski T, Molenberghs G, Buyse M, Geys H, Renard D. Validation of surrogate end points in multiple randomized clinical trials with failure time end points. J Roy Stat Soc C Appl Stat. 2001;50: 405-422.
63. Bruzzi P, Del Mastro L, Sormani M P, et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol. 2005;23:5117-5125.
64. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26:1987-1992.
65. Tsujino K, Kawaguchi T, Kubo A, et al. Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. J Thorac Oncol. 2009;4:994-1001.